Danaher and NVIDIA Partner to Accelerate Autonomous Science

Danaher is stepping up efforts to influence the future of AI-enabled science.

Just days after announcing plans to launch its “first AI-powered autonomous lab”, the diagnostics giant announced a partnership with the world’s most valuable company and AI technology innovator, NVIDIA, to “advance autonomous science.”

The collaboration combines Danaher’s scientific instruments, automation technologies, laboratory workflow software and life sciences expertise with NVIDIA’s accelerated computing and AI capabilities. 

By integrating these technologies, the companies aim to help researchers move more quickly from computational predictions to experimental validation, creating a continuous feedback loop in which experimental results refine AI models and those models inform the design of future experiments.

“By combining Danaher's workflows, data and deep scientific expertise with NVIDIA's AI and accelerated computing capabilities, we're creating a faster, more connected research process,” writes Danaher CEO Julie Sawyer Montgomery on LinkedIn.

“The goal is a continuous cycle where experiments improve AI models, and those models help scientists design better experiments.

“And that's what gets me excited. Helping researchers move faster to advance discoveries that can improve patients' lives.”

Danaher’s announcement fits into a wider shift in the industry, with Roche also revealing it is developing autonomous, AI-driven laboratories to accelerate R&D and drug discovery, alongside a wider push towards “AI independence” across its research operations. 

Edge computing integration

Danaher and NVIDIA are exploring ways to integrate AI into scientific instruments, combining edge computing, accelerated data processing and real-time inference with scientific reasoning and foundation models, including BioNeMo Open Models. 

Edge computing integration

Danaher and NVIDIA are exploring ways to integrate AI into scientific instruments, combining edge computing, accelerated data processing and real-time inference with scientific reasoning and foundation models, including BioNeMo Open Models. 

Initial work will focus on a select group of priority instruments, with scope to expand across Danaher’s wider portfolio. 

The companies are also investigating how physical AI technologies, including NVIDIA Cosmos world models and Omniverse digital twins, could enhance laboratory instruments and workflows, while ensuring experimental evidence remains central to scientific decision-making. 

NVIDIA’s Vice President of Healthcare, Kimberley Powell, says the collaboration will help bridge the gap between AI-driven predictions and practical experimentation, potentially accelerating the pace of scientific discovery.

"The next era of scientific discovery will be driven by a continuous loop between AI and experimentation," she says. 

"Together with Danaher, we are bringing accelerated computing and physical AI into the lab - connecting models with instruments and real experimental data, where experiments improve models and models design better experiments, helping researchers compress years of discovery into months." 

NVIDIA’s healthcare involvement

NVIDIA’s collaboration with Danaher builds on its wider push to apply AI across healthcare and life sciences, from drug discovery and medical imaging to clinical workflows and laboratory automation. 

Its BioNeMo platform provides tools and models for AI-driven biology, supporting applications including molecular design, protein structure prediction and virtual screening.

The company is also working with pharmaceutical leaders to integrate AI into research and development. 

In January 2026, NVIDIA and Eli Lilly announced plans for a co-innovation lab focused on drug discovery, while Roche is deploying NVIDIA computing infrastructure to support pharmaceutical research, diagnostics and manufacturing.

This growing ecosystem reflects NVIDIA’s ambition to connect AI models with real-world scientific data and experimentation. 

Danaher - key partners

Automata

CEO: Mostafa ElSayed  | HQ: London, UK

Automata is a laboratory automation company developing AI-ready infrastructure for life sciences research. Its LINQ platform connects laboratory instruments, robotics and software to automate complex experimental workflows. Danaher invested in Automata’s US$45m Series C in January 2026, while Automata’s technology is being used for device orchestration and robotic automation in Danaher’s upcoming autonomous lab.

AstraZeneca

CEO: Pascal Soriot | HQ: Cambridge, UK

AstraZeneca is a global biopharmaceutical company focused on discovering, developing and commercialising medicines across areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology. Danaher and AstraZeneca established a partnership in 2025 to develop and commercialise novel diagnostic tools, including AI-powered diagnostics, designed to help identify patients most likely to benefit from precision medicines. 

Innovaccer

CEO: Abhinav Shashank | HQ: San Francisco, California

Innovaccer develops AI-powered healthcare technology designed to connect data, applications and workflows across healthcare organisations. Danaher Ventures has described Innovaccer as a strategic AI-centric partner focused on patient health, with the relationship extending beyond investment into potential co-development, co-marketing and co-distribution opportunities. The partnership reflects Danaher’s broader strategy of combining external digital innovation with its life sciences and healthcare portfolio.